| Name | Title | Contact Details |
|---|
ATCC, the premier global biological materials resource and standards organization serves and supports the scientific community with industry-standard products and innovative solutions. With the world’s largest and most diverse collection of human and animal cell lines, microorganisms, nucleic acids, molecular genomic tools, and biological products, ATCC is a trusted resource for the worldwide research community. Together, the people of ATCC share in its mission to acquire, authenticate, preserve, develop, and distribute biological materials and information for the advancement of scientific knowledge.
Delfi is developing a new class of liquid biopsy tests for early detection based on altered genome-wide fragmentation profiles, also known as "fragmentomes," representing aberrant packaging of DNA in cancer cells. By applying advanced machine learning algorithms, these fragment patterns are detectable at a very low sequencing cost. Delfi is using this technology to develop highly sensitive and specific cancer detection assays intended for wide and cost-effective distribution and adoption.
Phosplatin Therapeutics is a private, clinical stage biopharmaceutical company founded in 2010, and funded by private investors and family investment offices in the U.S., Europe and Asia.
Boston BioCom is a Boston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Incept BioSystems is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.